title: Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.
abstract: Parkinson's disease (PD) patients experience loss of normal motor function (hypokinesia), but can develop uncontrollable movements known as dyskinesia upon treatment with L-DOPA. Poverty or excess of movement in PD has been attributed to overactivity of striatal projection neurons forming either the indirect (iSPNs) or the direct (dSPNs) pathway, respectively. Here, we investigated the two pathways' contribution to different motor features using SPN type-specific chemogenetic stimulation in rodent models of PD (PD mice) and L-DOPA-induced dyskinesia (LID mice). Using the activatory Gq-coupled human M3 muscarinic receptor (hM3Dq), we found that chemogenetic stimulation of dSPNs mimicked, while stimulation of iSPNs abolished the therapeutic action of L-DOPA in PD mice. In LID mice, hM3Dq stimulation of dSPNs exacerbated dyskinetic responses to L-DOPA, while stimulation of iSPNs inhibited these responses. In the absence of L-DOPA, only chemogenetic stimulation of dSPNs mediated through the Gs-coupled modified rat muscarinic M3 receptor (rM3Ds) induced appreciable dyskinesia in PD mice. Combining D2 receptor agonist treatment with rM3Ds-dSPN stimulation reproduced all symptoms of LID. These results demonstrate that dSPNs and iSPNs oppositely modulate both therapeutic and dyskinetic responses to dopamine replacement therapy in PD. We also show that chemogenetic stimulation of different signaling pathways in dSPNs leads to markedly different motor outcomes. Our findings have important implications for the design of effective antiparkinsonian and antidyskinetic drug therapies.
authors.forename: Cristina
authors.initials: C
authors.lastname: Alcacer
authors.forename: Laura
authors.initials: L
authors.lastname: Andreoli
authors.forename: Irene
authors.initials: I
authors.lastname: Sebastianutto
authors.forename: Johan
authors.initials: J
authors.lastname: Jakobsson
authors.forename: Tim
authors.initials: T
authors.lastname: Fieblinger
authors.forename: Maria Angela
authors.initials: MA
authors.lastname: Cenci
mesh_terms: D000818:Animals; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D009434:Neural Pathways / Q000378:metabolism* / Q000473:pathology; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D043587:Receptor, Muscarinic M3 / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D014793:Visual Cortex / Q000378:metabolism* / Q000473:pathology
chemical_list: D043587:Receptor, Muscarinic M3; D017448:Receptors, Dopamine D2; D007980:Levodopa